Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Jim Cramer recently called out the markets for not recognizing the potential of Sorrento Therapeutics and SRNE stock. Is he right?

The Next Bull Run Will Be Harder For Sorrento Therapeutics

Analysts are intrigued by the biopharmaceutical company's new coronavirus test.

Why Sorrento Therapeutics Stock Soared Today

From relative obscurity to generated headlines, SRNE stock has jumped on big claims by Sorrento Therapeutics. You should think carefully about these three questions before placing a bet.

3 Key Questions to Answer Before Buying Sorrento Therapeutics Stock

SRNE stock is an underappreciated gem as the company's recent acquisition offers significant product-pipeline expansion.
The post Vision of a Covid-19 Breakthrough Makes Sorrento Therapeutics Stock a Buy appeared first on InvestorPlace.

Vision of a Covid-19 Breakthrough Makes Sorrento Therapeutics Stock a Buy

Sorrento's drugs could generate a few billion dollars of revenue by the end of 2021, making SRNE stock attractive for speculative investors.
The post Speculative Investors Should Buy Sorrento Stock appeared first on InvestorPlace.

Speculative Investors Should Buy Sorrento Stock

New York, New York--(Newsfile Corp. - July 27, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Sorrento Therapeutics, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Sorrento Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 27, 2020 - SRNE

Is  (SRNE) Outperforming Other Medical Stocks This Year?

Is Sorrento Therapeutics (SRNE) Outperforming Other Medical Stocks This Year?

New York, New York--(Newsfile Corp. - July 27, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Sorrento Therapeutics, Inc.

SRNE Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Sorrento Therapeutics, Inc Shareholders With Losses Exceeding $250K of Class Action and Lead Plaintiff Deadline: July 27, 2020

Los Angeles, California--(Newsfile Corp. - July 27, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sorrento Therapeutics, Inc.

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sorrento Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Aphria

Cadence Bank

Cronos Group

Nokia

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Analyst Stock Picks Under $10 With Massive Upside Potential

Sorrento intends to acquire SmartPharm to develop its pipeline of gene-encoded antibodies to treat COVID-19 and cancer.

Sorrento Therapeutics to Buy Its Coronavirus Vaccine Development Partner

The biotech plans to make an acquisition for an undisclosed sum.

Why Sorrento Therapeutics Stock Slipped Today

Los Angeles, California--(Newsfile Corp. - July 24, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sorrento Therapeutics, Inc.

MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sorrento Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SAN DIEGO and BOSTON, July 24, 2020 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and SmartPharm Therapeutics, Inc.

Sorrento Enters Into Letter Of Intent To Acquire SmartPharm And Develop Pipeline Of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies To Treat COVID-19 and Cancer Therapeutics

Vaxart

Which stock wins in a matchup between these clinical-stage biotechs?

Better Coronavirus Stock: Sorrento Therapeutics vs. Vaxart

Extreme volatility is name of the game with shares of small biotech companies such as Sorrento Therapeutics. Investors should be ready to embrace further choppiness in the coming weeks.

Sorrento Therapeutics May Be Ready For a Pullback

Los Angeles, California--(Newsfile Corp. - July 23, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sorrento Therapeutics, Inc.

DEADLINE MONDAY NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sorrento Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Sorrento Therapeutics (SRNE) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Earnings Estimates Moving Higher for Sorrento Therapeutics (SRNE): Time to Buy?

NEW YORK--(BUSINESS WIRE)-- #SRNE--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that purchased Sorrento Therapeutics, Inc.

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Sorrento Therapeutics, Inc.

New York, New York--(Newsfile Corp. - July 22, 2020) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Sorrento Therapeutics, Inc.

SRNE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 27, 2020 in the Class Action Filed on Behalf of Sorrento Therapeutics, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - July 22, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Sorrento Therapeutics, Inc.

SRNE Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Sorrento Therapeutics, Inc Shareholders With Losses Exceeding $250K of Class Action and Lead Plaintiff Deadline: July 27, 2020

Los Angeles, California--(Newsfile Corp. - July 22, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sorrento Therapeutics, Inc.

DEADLINE MONDAY REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sorrento Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - July 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sorrento Therapeutics, Inc.

DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sorrento Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The world wants a Covid-19 vaccine, but for biotech investors eyeing Sorrento for additional upside potential, there’s a better therapy for risk-adjusted returns in the options market

Why It’s Not Too Late to Buy SRNE Stock

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) stock jumped on Monday after the company announced that the U.S.

News for Sorrento Therapeutics Inc Stock (SRNE)